blue cross blue shield not covering glp 1 Excellus clarifies GLP-1 coverage ahead of 2026 formulary changes Alternatives to GLP-1 medication?

As a health insurer, though, it can get extremely expensive to cover these medicines for every patient

Glycemic Safety Of particular importance given the glucagon receptor agonism component of retatrutide, there were no clinically significant increases in blood glucose or concerning hyperglycemic events despite glucagon's classical glucose-raising effects - confirming that the GLP-1 component successfully counteracts glucagon's impact on glucose homeostasis

How Excellus BlueCross BlueShield (BCBS) helps employers manage this trend As the GLP-1 landscape evolves, we are dedicated to keeping our policies aligned with the latest data to ensure the best outcomes for your team

Its unique mechanism of action has positioned it as a compound of interest in the following research domains

Fralick, M., Colacci, M., Odutayo, A., Siemieniuk, R., & Glynn, R

FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s